NCT02959619View on ClinicalTrials.gov

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 6, 2017

Primary Completion Date

October 31, 2019

Study Completion Date

April 23, 2020

Conditions
Solid TumorNon-Small Cell Lung Cancer Metastatic
Interventions
DRUG

Ensartinib

Oral ensartinib was given daily at escalating doses in a 28-day cycle

Trial Locations (1)

510060

Sun yat-sen Univerisity Cancer Center, Guanzhou

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY